OCUL

OCUL is not an operating business you can value on its numbers — it's a binary clinical-stage option dressed as a $2.16B equity. The actual commercial product, DEXTENZA, generated just $52.0M in FY2025, and that revenue fell 18.5% year-over-year even as the loss ballooned to -$265.9M (a -511.9% net margin and -519.8% operating margin). Five years of history show no path to profitability: losses have widened every year from -$6.55M (FY2021) to -$266M (FY2025), and the company itself states in the 10-K that it 'may never achieve or maintain profitability' and expects to 'continue to incur significant expenses and operating losses over the next several years.' At 41.5x sales on a shrinking top line, the price discounts a pipeline outcome, not the business.

The entire equity value rests on AXPAXLI — the SOL registrational program in wet AMD and the HELIOS program in diabetic retinopathy. The data provided contains no trial results, no readout dates, and no probability of FDA approval. That is the definition of an unknowable, binary risk: the stock is worth multiples of today's price if SOL/HELIOS succeed and a fraction of it if they fail, and nothing in the supplied figures lets an analyst handicap that coin-flip. R&D spend jumped 54.4% to $197M, confirming management is pouring resources into these reads, which raises the stakes in both directions.